Concurrent administration of interferon alfa-2b and beta-1a

Annals of Pharmacotherapy

Volumn 37, Issue 1, 2003, Pages 77-79

  Tanvetyanon, Tawee ^a,b   Stadtmauer, Edward A ^c   Kerson, Lawrence A ^c  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Interferon; Multiple sclerosis; Myeloid leukemia

Indexed keywords

ALPHA2B INTERFERON; BETA1A INTERFERON;

ADULT; ANOREXIA; APPETITE DISORDER; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFLAMMATION; INJECTION SITE; INSOMNIA; LABORATORY TEST; MALE; MEMORY DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PHYSICAL DISABILITY; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; WEIGHT REDUCTION;

EID: 0037224485     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C120     Document Type: Article

References (14)

1. Albertini MR, Sondel PM. Tumor immunology and immunotherapy. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Abeloff Clinical Oncology. 2nd Ed. Philadelphia: Churchill Livingstone. 2000:214-30.
2. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murrey TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
3. McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997;19:395-7.
4. Kataoka I, Shinagawa K, Shiro Y, Okamoto S, Watanabe R, Mori T, et al. Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol 2002;70:149-53.
5. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994;330:820-5.
6. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-9.
7. Package Insert. Intron A (Interferon Alfa-2b, Recombinant for Injection). Kenilworth, NJ: Schering, August 2001.
8. Package Insert. Avonex (Interferon Beta-1a). Cambridge, MA: Biogen, July 2000.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
10. IRIS (International Randomized IFN vs. STI 571) Study Group. STI 571 (Gleevec/Glivec, imatinib) versus interferon (IFN) plus cytarabine as initial therapy for patients with CML: Results of a randomized study (abstract). Proc Am Soc Clin Oncol 2002;21:1a.
11. Walther EU, Hohlfeld R. Multiple sclerosis side effects of interferon beta therapy and their management. Neurology 1999;53:1622-7.
12. Kinkel RP, Rudick R, Ransohoff RM. Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon alpha 2b for metastatic renal cell carcinoma (letter). J Neurol Neurosurg Psychiatry 1997;62:100.
13. Larrey D, Marcellin P, Freneaux E, Pessayre D, Benhamou JP. Exacerbation of multiple sclerosis after the administration of recombinant human interferon alfa (letter). JAMA 1989;261:2065.
14. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, et al. Intravenous recombinant interferon beta versus interferon alpha 2b and ribavarin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group investigators. Scand J Gastroenterol 1999;34:928-33.